
Please try another search
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Robert Richard Ruffolo | 74 | 2018 | Independent Director & Member of Scientific Advisory Board |
Robert T. Connelly | 65 | 2018 | CEO, President & Director |
Darrell J. Irvine | - | - | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board |
Carol Gail Ashe | 67 | 2020 | Independent Director |
Julian Adams | 70 | 2017 | Independent Chairman & Member of Scientific Advisory Board |
Yekaterina Chudnovsky | 39 | 2022 | Director |
Karen J. Wilson | 62 | 2023 | Independent Director |
Adrian Bot | - | - | Member of Scientific Advisory Board |
Pashtoon Kasi | - | - | Member of Scientific Advisory Board |
Emanuele Ostuni | - | - | Member of Scientific Advisory Board |
Jay R. Venkatesan | 53 | 2016 | Director |
Allen Richard Nissenson | 78 | 2023 | Founder & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review